Cucurbitane triterpenoid from momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor γ activation

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Weng, Jing Ru ^a   Bai, Li Yuan ^b,c   Chiu, Chang Fang ^b   Hu, Jing Lan ^a   Chiu, Shih Jiuan ^d   Wu, Chia Yung ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA,7BETA DIHYDROXY 25 METHOXYCUCURBITA 5,23 DIENE 19 AL; ANTINEOPLASTIC AGENT; CASPASE 3; CHLOROQUINE; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN KINASE B; TRITERPENOID; TROGLITAZONE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOMORDICA CHARANTIA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84880170193     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/935675     Document Type: Article

References (49)

1. Ray R. B., Raychoudhuri A., Steele R., Nerurkar P., Bitter Melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Research 2010 70 5 1925 1931 2-s2.0-77950278220 10.1158/0008-5472.CAN-09-3438
2. Jilka C., Strifler B., Fortner G. W., In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Research 1983 43 11 5151 5155 2-s2.0-0021025259
3. Soundararajan R., Prabha P., Rai U., Antileukemic potential of Momordica charantia seed extracts on human myeloid leukemic HL60 cells. Evidence-Based Complementary and Alternative Medicine 2012 2012 10 732404 10.1155/2012/732404
4. Ru P., Steele R., Nerurkar P. V., Phillips N., Ray R. B., Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prevention Research 2011 4 12 2122 2130 2-s2.0-83055174654 10.1158/1940-6207.CAPR-11-0376
5. Brennan V. C., Wang C., Yang W., Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC- α serine/threonine-protein kinase signaling. Journal of Medicinal Food 2012 15 4 325 334 2-s2.0-84859061077 10.1089/jmf.2011.0158
6. Scartezzini P., Speroni E., Review on some plants of Indian traditional medicine with antioxidant activity. Journal of Ethnopharmacology 2000 71 1-2 23 43 2-s2.0-0033918062 10.1016/S0378-8741(00)00213-0
7. Lii C. K., Chen H. W., Yun W. T., Liu K., Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW 264.7 macrophages. Journal of Ethnopharmacology 2009 122 2 227 233 2-s2.0-60849121701 10.1016/j.jep.2009.01.028
8. Shih C. C., Lin C. H., Lin W. L., Wu J., Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. Journal of Ethnopharmacology 2009 123 1 82 90 2-s2.0-64549141112 10.1016/j.jep.2009.02.039
9. Wang Z. Q., Zhang X. H., Yu Y., Poulev A., Ribnicky D., Floyd Z. E., Cefalu W. T., Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. Journal of Nutritional Biochemistry 2011 22 11 1064 1073 2-s2.0-80053362207 10.1016/j.jnutbio.2010.09.004
10. Chao C. Y., Yin M. C., Huang C. J., Wild bitter gourd extract up-regulates mRNA expression of PPAR α PPAR γ and their target genes in C57BL/6J mice. Journal of Ethnopharmacology 2011 135 1 156 161 2-s2.0-79955464109 10.1016/j.jep.2011.03.001
11. Tsai C. H., Chen E. C., Tsay H. S., Huang C. J., Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial. Nutrition Journal 2012 11 1 4 2-s2.0-84855730976 10.1186/1475-2891-11-4
12. Jeong S., Yoon M., 17 β -Estradiol inhibition of PPAR γ -induced adipogenesis and adipocyte-specific gene expression. Acta Pharmacologica Sinica 2011 32 2 230 238 2-s2.0-79551669498 10.1038/aps.2010.198
13. Jiang Y., Huang Y., Cheng C., Lu W., Zhang Y., Liu X., Zou L., Ben Q., Shen A., Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPAR γ up-expression in MDA-MB-231 cells. Experimental and Molecular Pathology 2011 91 3 768 774 2-s2.0-80054072725 10.1016/j.yexmp.2011.09.007
14. Rusinova R., Herold K. F., Lea Sanford R., Greathouse D. V., Hemmings H. C., Andersen O. S., Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. Journal of General Physiology 2011 138 2 249 270 2-s2.0-79961107148 10.1085/jgp.201010529
15. Zhou J., Zhang W., Liang B., Casimiro M. C., Whitaker-Menezes D., Wang M., Lisanti M. P., Lanza-Jacoby S., Pestell R. G., Wang C., PPAR γ activation induces autophagy in breast cancer cells. International Journal of Biochemistry and Cell Biology 2009 41 11 2334 2342 2-s2.0-70349298359 10.1016/j.biocel.2009.06.007
16. Weng J. R., Chen C. Y., Pinzone J. J., Ringel M. D., Chen C. S., Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocrine-Related Cancer 2006 13 2 401 413 2-s2.0-33745113772 10.1677/erc.1.01182
17. Yu N. H., Lee Y. R., Noh E. M., Lee K., Kim J., Song E., Han M., Lee Y., Kwon K., Lee S., Youn H. J., Jung S. H., Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPAR γ) ligand. Cell Biology International 2008 32 8 906 912 2-s2.0-47349108152 10.1016/j.cellbi. 2008.04.011
18. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R. A., Martinez G., Inestrosa N. C., Bronfman M., Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. Journal of Biological Chemistry 2007 282 51 37006 37015 2-s2.0-37549060702 10.1074/jbc.M700447200
19. Liu J. J., Liu P. Q., Lin D. J., Xiao R., Huang M., Li X., He Y., Huang R., Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor- γ agonists induced apoptosis in human monocyte leukemia cells in vitro. Annals of Hematology 2007 86 3 173 183 2-s2.0-33846651029 10.1007/s00277-006-0205-2
20. Teresi R. E., Shaiu C. W., Chen C. S., Chatterjee V. K., Waite K. A., Eng C., Increased PTEN expression due to transcriptional activation of PPAR γ by Lovastatin and Rosiglitazone. International Journal of Cancer 2006 118 10 2390 2398 2-s2.0-33646434260 10.1002/ijc.21799
21. Colin C., Salamone S., Grillier-Vuissoz I., Boisbrun M., Kuntz S., Lecomte J., Chapleur Y., Flament S., New troglitazone derivatives devoid of PPAR γ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Research and Treatment 2010 124 1 101 110 2-s2.0-77957719908 10.1007/s10549-009-0700-y
22. Koeffler H. P., Peroxisome proliferator-activated receptor γ and cancers. Clinical Cancer Research 2003 9 1 1 9 2-s2.0-0037235020
23. Fenner M. H., Elstner E., Peroxisome proliferator-activated receptor- γ ligands for the treatment of breast cancer. Expert Opinion on Investigational Drugs 2005 14 6 557 568 2-s2.0-21244432740 10.1517/13543784.14. 6.557
24. Zhang J., Huang Y., Kikuchi T., Tokuda H., Suzuki N., Inafuku K., Miura M., Motohashi S., Suzuki T., Akihisa T., Cucurbitane triterpenoids from the leaves of Momordica charantia, and their cancer chemopreventive effects and cytotoxicities. Chemistry and Biodiversity 2012 9 2 428 440 2-s2.0-84857301978 10.1002/cbdv.201100142
25. Mulholland D. A., Sewram V., Osborne R., Pegel K. H., Connolly J. D., Cucurbitane triterpenoids from the leaves of Momordica foetida. Phytochemistry 1997 45 2 391 395 2-s2.0-0030891197 10.1016/S0031-9422(96)00814-X
26. Weng J. R., Tsai C. H., Kulp S. K., Chen C. S., Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Letters 2008 262 2 153 163 2-s2.0-40649107590 10.1016/j.canlet.2008.01.033
27. Hou Y., Moreau F., Chadee K., PPAR γ is an E3 ligase that induces the degradation of NF B/p65. Nature Communications 2012 3 1300 10.1038/ncomms2270
28. Lecomte J., Flament S., Salamone S., Boisbrun M., Mazerbourg S., Chapleur Y., Grillier-Vuissoz I., Disruption of ER α signalling pathway by PPAR γ agonists: evidences of PPAR γ -independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Research and Treatment 2008 112 3 437 451 2-s2.0-56549115139 10.1007/s10549-007-9886-z
29. Weber S. M., Chambers K. T., Bensch K. G., Scarim A. L., Corbett J. A., PPAR γ ligands induce ER stress in pancreatic β -cells: ER stress activation results in attenuation of cytokine signaling. American Journal of Physiology 2004 287 6 E1171 E1177 2-s2.0-8544267219 10.1152/ajpendo.00331.2004
30. Oyadomari S., Mori M., Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death and Differentiation 2004 11 4 381 389 2-s2.0-1842843855 10.1038/sj.cdd.4401373
31. Ron D., Walter P., Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews Molecular Cell Biology 2007 8 7 519 529 2-s2.0-34250899722 10.1038/nrm2199
32. Klionsky D. J., Cregg J. M., Dunn W. A. Jr., Emr S. D., Sakai Y., Sandoval I. V., Sibirny A., Subramani S., Thumm M., Veenhuis M., Ohsumi Y., A unified nomenclature for yeast autophagy-related genes. Developmental Cell 2003 5 4 539 545 2-s2.0-10744225487 10.1016/S1534-5807(03)00296-X
33. Liang X. H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., Levine B., Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999 402 6762 672 676 2-s2.0-0000906170 10.1038/45257
34. Meijer A. J., Dubbelhuis P. F., Amino acid signalling and the integration of metabolism. Biochemical and Biophysical Research Communications 2004 313 2 397 403 2-s2.0-0347627140 10.1016/j.bbrc.2003.07.012
35. Meijer A. J., Codogno P., AMP-activated protein kinase and autophagy. Autophagy 2007 3 3 238 240 2-s2.0-34248593475
36. Shen Z., Wen X. F., Lan F., Shen Z., Shao Z., The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clinical Cancer Research 2002 8 7 2085 2090 2-s2.0-0035992276
37. Codogno P., Meijer A. J., Autophagy and signaling: their role in cell survival and cell death. Cell Death and Differentiation 2005 12 supplement 2 1509 1518 2-s2.0-27644466759 10.1038/sj.cdd.4401751
38. Fan Q. W., Cheng C., Hackett C., Feldman M., Houseman B. T., Nicolaides T., Haas-Kogan D., James C. D., Oakes S. A., Debnath J., Shokat K. M., Weiss W. A., Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science Signaling 2010 3 147 ra81 2-s2.0-78149475478 10.1126/scisignal.2001017
39. Shintani T., Klionsky D. J., Autophagy in health and disease: a double-edged sword. Science 2004 306 5698 990 995 2-s2.0-8344242220 10.1126/science.1099993
40. Li H. B., Wong C. C., Cheng K. W., Chen F., Antioxidant properties in vitro and total phenolic contents in methanol extracts from medicinal plants. LWT-Food Science and Technology 2008 41 3 385 390 2-s2.0-36348987254 10.1016/j.lwt.2007.03.011
41. Yuan X. Q., Gu X. H., Tang J., Wasswa J., Hypoglycemic effect of semipurified peptides from Momordica charantia L. var. Abbreviata Ser. in alloxan-induced diabetic mice. Journal of Food Biochemistry 2008 32 1 107 121 2-s2.0-38949083117 10.1111/j.1745-4514.2007.00150.x
42. Bonofiglio D., Gabriele S., Aquila S., Catalano S., Gentile M., Middea E., Giordano F., Andò S., Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells. Clinical Cancer Research 2005 11 17 6139 6147 2-s2.0-24344455975 10.1158/1078-0432.CCR-04-2453
43. Yan J., Yang H., Wang G., Sun L., Zhou Y., Guo Y., Xi Z., Jiang X., Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling. Autophagy 2010 6 1 67 73 2-s2.0-75149126171 10.4161/auto.6.1.10437
44. Kim J., Kundu M., Viollet B., Guan K., AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature Cell Biology 2011 13 2 132 141 2-s2.0-79551598347 10.1038/ncb2152
45. LeBrasseur N. K., Kelly M., Tsao T., Farmer S. R., Saha A. K., Ruderman N. B., Tomas E., Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. American Journal of Physiology 2006 291 1 E175 E181 2-s2.0-33745869049 10.1152/ajpendo.00453.2005
46. Lee W. H., Kim S. G., AMPK-dependent metabolic regulation by PPAR agonists. PPAR Research 2010 2010 10 2-s2.0-77956842224 10.1155/2010/549101 549101
47. Shackelford D. B., Shaw R. J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer 2009 9 8 563 575 2-s2.0-67749111502 10.1038/nrc2676
48. Bartholomeusz C., Gonzalez-Angulo A. M., Targeting the PI3K signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012 16 1 121 130 2-s2.0-84855895252 10.1517/14728222.2011.644788
49. O'Reilly K. E., Rojo F., She Q., Solit D., Mills G. B., Smith D., Lane H., Hofmann F., Hicklin D. J., Ludwig D. L., Baselga J., Rosen N., mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 2006 66 3 1500 1508 2-s2.0-32944457518 10.1158/0008-5472. CAN-05-2925 Hospital Cancer Research of Excellence